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When faced with an increased threshold
of oncogenic signals that provoke cells to
divide at an abnormally accelerated
pace, the Arf tumor suppressor gene is
activated. Its encoded product (p19Arf in
mouse or p14ARF in humans) antagonizes
the ubiquitin E3 protein ligase activity of
the p53 negative regulator Mdm2 (Hdm2
in humans) to trigger a p53-dependent
transcriptional response that leads to
either cell cycle arrest or apoptosis.
These protective responses can be dis-
abled through deletion or silencing of Arf,
by generation of dominant-negative
mutants of p53, or through mechanisms
leading to Mdm2 overexpression, so
enabling incipient cancer cells to thrive.
Myc was the first oncogene recog-
nized to activate Arf gene expression
(Zindy et al., 1998), although the mecha-
nism by which it does so remains unclear.
When Myc expression is enforced in
mouse B-lymphocytes in vivo, its enhanc-
ing effects on cell proliferation are inhibit-
ed by the Arf-Mdm2-p53 axis, but dis-
abling the pathway cancels Myc-induced
apoptosis and allows formation of B cell
lymphomas (Eischen et al., 1999).
Observations that Myc could trigger a p53
response through the agency of Arf were
conceptually satisfying, but additional
complexities soon became apparent.
First, high and sustained Myc activity is
required for Arf induction, but the promot-
er is normally insulated from responding
to physiologic Myc signals. Second, cells
lacking p53 or harboring mutant forms of
the protein display dramatic upregulation
of p19Arf, and reintroduction of p53
represses Arf transcription. This feedback
control by p53 also extends to c-Myc,
again through an unknown mechanism
(Figure 1). Most importantly, however,
mice engineered to lack both Arf and p53,
or all three genes in the pathway, develop
(usually multiple) cancers at a faster rate,
and the spectrum of tumor types arising in
these mice is much broader than that of
animals lacking either Arf or p53, or both
Mdm2 and p53, providing genetic evi-
dence that p19Arf must have p53-indepen-
dent functions (Weber et al., 2000).
Indeed, cells lacking Arf and p53 prolifer-
ate faster than those lacking either gene
alone, and enforced overexpression of Arf
can arrest the proliferation of p53 null
mouse embryo fibroblasts (MEFs), albeit
inefficiently (Eischen et al., 1999; Weber
et al., 2000).
Recent studies now suggest that
p19Arf can negatively regulate Myc’s tran-
scriptional activity through a direct physi-
cal interaction that is seemingly
independent of Mdm2 and p53 (Qi et al.,
2004). These investigators report some
surprising findings that include Myc’s abil-
ity to bind directly to Arf and to relocalize
Arf from its usual storehouse in the nucle-
olus into the nucleoplasm in both wild-
type and p53-deficient MEFs. Most
striking, however, are their observations
that p19Arf associates with Myc on its tar-
Antagonism of Myc functions by Arf
The Arf-Mdm2-p53 tumor suppressor pathway is activated by sustained hyperproliferative signals emanating from onco-
proteins such as Myc. A recent study reveals a novel level of feedback control, whereby induced p19Arf binds to Myc and
blocks cell proliferation by selectively impairing its transactivation functions.
310 CANCER CELL : OCTOBER 2004
get genes, antagonizing Myc’s
transactivation functions with-
out impairing its transrepres-
sion activities (Figure 1).
Specifically, chromatin immuno-
precipitation (ChIP) analysis
revealed that the Arf protein
binds to the promoters of the
eIF4E and nucleolin genes
upon Myc activation. Myc bind-
ing to these promoters occurs
whether or not Arf and/or p53
genes are present, indicating
that p19Arf does not affect the
recruitment of Myc to its target
genes. Myc induced the expres-
sion of eIF4e, nucleolin, Tert,
Cdk4, and Cul1 in Arf/p53 dou-
ble null cells, but not in p53 null
MEFs that express very high
levels of endogenous p19Arf. In
contrast, downregulation of
Gadd45 and Ink4b by Myc was
unaffected by Arf status.
Together, these results point to
a new component of feedback
regulation where, following its
induction by Myc, p19Arf directly
and selectively inhibits Myc’s
pro-proliferative activities in 
a p53-independent manner
(Figure 1).
What are the potential limi-
tations of the analysis? First, p19Arf is a
highly basic and “sticky” protein (pI > 12)
with a propensity to bind nucleic acids and
acidic proteins even under stringent
detergent lysis conditions. With its unusu-
al amino acid composition, p19Arf may well
interact nonspecifically with other mole-
cules, and it is difficult to devise appropri-
ate experimental controls that deal
effectively with this problem. Perhaps not
surprisingly, then, Arf has been demon-
strated to coimmunoprecipitate with a
number of cellular proteins other than
Mdm2, including nucleophosmin (at high
stoichiometry), E2F1 and DP1, HIF-1α,
topoisomerase I, TBP-1, spinophilin,
Pex19p, and cyclin G1, although the phys-
iologic significance of these interactions
remains uncertain. It has also proven diffi-
cult to map Arf binding sites within many
of these putative target proteins. Qi et al.
(2004) found that Arf could bind to both
the N- and C-terminal domains of Myc,
which include the transcriptional regulato-
ry and the helix-loop-helix/leucine zipper
domains, respectively, although the for-
mer segment seems to represent the pri-
mary binding site. Second, the authors
observed that overexpressed Myc could
interact with p19Arf in the nucleoplasm of
MEFs to prevent its entry into the nucleo-
lus, but in other cell lines, the two proteins
localized to nucleoli, as was also
observed by others (Datta et al., 2004).
This seems reminiscent of the Arf-Mdm2
interaction in which enforced overexpres-
sion of Mdm2 relocalized p19Arf to the
nucleoplasm; conversely, overexpression
of Arf led to Mdm2 sequestration within
the nucleolus (reviewed in Sherr and
Weber, 2000). In fact, the results of Qi et
al. (2004) also contradict previous results
indicating that conditional Myc activation
in MEFs provoked accumulation of p19Arf,
and then Mdm2, within the nucleolus. A
caveat for all such studies is that they
have generally relied upon diverse cell
types and vectors that overexpress vastly
different amounts of proteins. This under-
scores the potential difficulties in deter-
mining where within cells Arf antagonism
of Myc may occur.
Myc affects not only cell proliferation
but also cell growth (mass).At least in part,
this may be due to its ability to
activate Pol I- and Pol III-depen-
dent transcription (affecting the
synthesis of rRNAs, 5S RNA,
and tRNAs) and to accelerate
rRNA processing (Schlosser et
al., 2003; Gomez-Roman et al.,
2003). As would be expected,
some Myc protein localizes to
nucleoli, where its turnover is
regulated by an SCF E3 ubiqui-
tin ligase that includes the
Fbw7γ F box specificity factor;
interference with Myc deg-
radation in this compartment
increases cell size (Welker et
al., 2004). Intriguingly, Arf
inhibits ribosome biogenesis by
interfering with rRNA process-
ing (Sugimoto et al., 2003) and,
by ChIP, binds to rDNA promot-
ers (Ayrault et al., 2004).
Therefore, the primordial role of
Arf may have been to control
cell growth in a p53-indepen-
dent manner, but in the course
of evolution, Arf may have
acquired the capacity to effi-
ciently arrest cell proliferation by
binding to Mdm2 and activating
p53. In light of these new
results, this begs the question of
whether p19Arf interacts directly
with Myc on rDNA promoters.
Does inhibition of Myc function by Arf
coordinately inhibit both proliferation and
growth in incipient cancer cells? For pro-
liferating cells to maintain their size, coor-
dination of these processes is vital. The
mechanisms that link the cell division
cycle with ribosome production, protein
and membrane biosynthesis, nutrient
availability, cellular metabolism, and
energy production are not clearly under-
stood. Perhaps Myc is a master regulator
of these processes. A further understand-
ing of Arf-Myc antagonism will require a
more detailed examination of their physi-
cal interactions on a broader spectrum of
Myc target genes.
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Figure 1. Feedback controls affecting the activities of Myc
and Arf
Myc induces Arf transcription to trigger a p53 response. p53 acti-
vates Mdm2, whereas p19Arf inhibits it. p53 also negatively regu-
lates the transcription of both Arf and Myc. Myc-Max complexes
have global effects on chromatin structure, activating numerous
target genes by binding to CACGTG consensus sequences and
repressing other targets by interacting with Miz-1 on promoter ini-
tiator elements (Inr). The p19Arf protein is now revealed to inhibit
the activity of Myc on its target promoters (shaded portions of the
schematic) (Qi et al., 2004). This antagonism is selective, blocking
Mycs ability to activate gene expression, but not affecting gene
repression. In turn, Arf cancels Mycs pro-proliferative, but not its
apoptotic, functions. We speculate that Arfs ability to antago-
nize Myc also negatively regulates cell growth (mass).
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